Agency to join

I-Mab Reports Third Quarter 2024 Results

I-Mab Biopharma

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study ofuliledlimab in first-line mNSCLC in 1H 2025

Home Previous 53 54 55 56 57 58 59 Next Tail

10 Items Per Page (Page 56 / 130) Total 1299 Items

©copyright 2009-2020 Bit Bit Daily      Contact Us   SiteMap